MacrogenicsMGNX +1.92%47 Dividend Yield % is 0.00% as of Jun. 25, 2026. GuruFocus rates MGNX with a GF Score™ of 47/100 and a GF Value™ of $4.09 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 151 Biotechnology companies, Macrogenics ranks worse than 662250.99% on this metric.
As of today (2026-06-25), the Trailing Annual Dividend Yield of Macrogenics is 0.00%.
The historical rank and industry rank for Macrogenics's Dividend Yield % or its related term are showing as below:
MGNX's Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.51 * Ranked among companies with meaningful Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
The historical data trend for Macrogenics's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MGNX vs CNTX, TARA, ACIU: Dividend Yield % Comparison
For the Biotechnology subindustry, Macrogenics's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Macrogenics Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Macrogenics's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Macrogenics's Dividend Yield % falls into.
Macrogenics (MGNX) has a Dividend Yield % of 0.00% as of Jun. 25, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Macrogenics and its competitors. According to the industry distribution chart, Macrogenics ranks #999999 out of 151 companies in the Biotechnology industry.
Is Macrogenics' Dividend Yield % too high?
Macrogenics' current Dividend Yield % is 0.00%. Based on the distribution chart, Macrogenics ranks #999999 out of 151 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Macrogenics has a GF Score™ of 47/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Macrogenics' Dividend Yield % compare to CNTX and TARA?
According to the Biotechnology industry distribution chart, Macrogenics ranks #999999 out of 151 companies for Dividend Yield %. This places Macrogenics in the lower half of its industry. The industry median Dividend Yield % is 1.51. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Biotechnology company?
The median Dividend Yield % among Biotechnology companies is 1.51, based on 151 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Macrogenics and its competitors. For the Biotechnology industry, the median Dividend Yield % is 1.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Macrogenics's current Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Macrogenics stock overvalued right now?
Based on GuruFocus' analysis, Macrogenics (MGNX) is currently considered Modestly Overvalued. The stock's GF Value™ is $4.09, compared to a current price of $4.76 — trading 16.4% above its estimated fair value. The current Dividend Yield % is 0.00%. Macrogenics' overall GF Score™ is 47/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Macrogenics (MGNX), the current Dividend Yield % is 0.00% as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Macrogenics (MGNX) Overvalued in 2026?
Based on GuruFocus' analysis, Macrogenics stock appears to be overvalued.
The current stock price of $4.76 is trading 16.4% above its estimated GF Value™ of $4.09.
GuruFocus considers Macrogenics to be Modestly Overvalued.
Key valuation signals for MGNX:
Dividend Yield %: 0.00%
GF Value™: $4.09 vs. price of $4.76 (16.4% above fair value)
No single metric tells the full story. See the MGNX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
47GF Score
Get the complete analysis for MGNX
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MGNX has been successfully added to your 
